Article (Published version) (636 Kb) - 
Limited access to UNIGE
Highlights
More informations
Scientific Article
unige:39529 
 |
Ostéonécrose des maxillaires et bisphosphonates |
|
| Authors | ||
| Published in | Revue médicale suisse. 2005, vol. 1, no. 39, p. 2537-40,2542-3 | |
| Abstract | Widely prescribed, bisphosphonates inhibit bone resorption. They are not metabolised and have long half-lives. Two cases of osteonecrosis of the jaws have recently been attributed to bisphosphonates at the University Hospital of Geneva. The recent literature reveals more than a hundred similar cases throughout the world. Bone exposure appears spontaneously or after dental care. Treatment of the osteonecrosis is controversial and cure very difficult. This pathology is usually seen in patients on chemotherapy, steroids and i.v. bisphosphonates, but is sometimes seen with low-dose p.o. bisphosphonates. In view of the strong association between bisphosphonate therapy and osteonecrosis of the jaw, specialists have recommended dental and oral evaluation during bisphosphonate therapy as well as for several years after drug discontinuation. | |
| Keywords | Age Factors — Diphosphonates/administration & dosage/adverse effects/therapeutic use — Drug Interactions — Humans — Infusions, Intravenous — Jaw/pathology — Osteonecrosis/chemically induced — Steroids/therapeutic use | |
| Identifiers | PMID: 16323736 | |
| Full text | ||
| Structures | ||
| Research groups | Groupe Lombardi Tommaso (médecine dentaire) (313) Groupe Scolozzi Paolo (chirurgie maxillo-faciale et buccale) (896) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) | |
| Citation (ISO format) | JUNOD, Alain et al. Ostéonécrose des maxillaires et bisphosphonates. In: Revue médicale suisse, 2005, vol. 1, n° 39, p. 2537-40,2542-3. https://archive-ouverte.unige.ch/unige:39529 |
241 hits 
1 download 
Contact an author
Update